肺腺癌的综合性多组和免疫分析:分子景观,基因表达和治疗反应见解

相关实验视频

Updated: May 13, 2026

08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.1K

Yahui Tian¹, Honghong Dong¹, Yujie Guo^1,2

¹Department of Thoracic Surgery, Air Force Medical Center, Fourth Military Medical University, Beijing, 100142, China.

The oncologist

|June 24, 2025

概括

这项研究确定了两个具有明显分子和免疫特征的肺腺癌 (LUAD) 亚型,改善了预后预测. 一个下调的基因NDNF显示了向LUAD治疗的瘤抑制潜力.

科学领域:

在瘤学瘤学.
基因组学就是基因组学.
免疫学免疫学免疫学

背景情况:

肺腺癌 (LUAD) 具有显著的死亡风险.
目前的组织病理学分类未能捕捉到LUAD的分子多样性,阻碍了个性化治疗.
多原子数据集成对于完善LUAD分类和治疗策略至关重要.

研究的目的:

使用多原子数据来定义LUAD亚型.
评估已识别的LUAD亚型的预后和治疗影响.
研究NDNF在LUAD进展中的作用及其作为治疗点的潜力.

主要方法:

对多原子数据 (mRNA, lncRNA, miRNA,甲基化,突变) 应用的共识聚类和差距统计.
分子特征包括 regulon 活性,免疫和代谢概况.
功能性测试 (qPCR,WB,CCK-8,流细胞计) 评估了在LUAD中NDNF的功能.

主要成果:

确定了两种不同的LUAD分子亚型,具有差异性的生存结果.
一个亚型呈现出较差的预后和独特的免疫微环境特征,包括检查点表达.
发现NDNF在LUAD下调,其过度表达通过抑制细胞活力和促进细胞亡,显示出瘤抑制活性.

结论:

该研究定义了两个具有明显分子,免疫和预后特征的LUAD亚型,使得患者的分层化得到改善.
在LUAD中NDNF的瘤抑制功能和下调突出了其作为预后生物标志物和治疗点的潜力.
这些发现为加强LUAD分类和开发个性化治疗策略铺平了道路.

关键词:

不同基因表达的差异性进行免疫分析.肺部腺癌是肺部腺癌.分子子类型分子子类型多种组合的多种组合.个性化医疗是个性化的医疗.

相关概念视频

02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...